ReviewDiabetology & metabolic syndrome2023
Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis.
Review in Diabetology & metabolic syndrome, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 5 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Antidiabetic Effects of Anthocyanins on Pancreatic β-Cell Function: A Systematic Review ofInternational journal of molecular sciences · 2026Pooled it
- Risk factors for diabetic kidney disease in type 2 diabetes mellitus in Asia: a meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Incidence and predictors of diabetic kidney disease among type 2 diabetes mellitus adult patients in Ethiopia: a systematic review and meta-analysis.BMC endocrine disorders · 2025Pooled it
- Pooled it
- Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6.Diabetes, obesity & metabolism · 2025Trial
- Determinants of hypoglycemia and hospitalization among hemodialysis patients with type 2 diabetes: insights from a multicenter study in a resource-limited healthcare system.Renal failure · 2026Article
- Diabetogenic effects of arsenic exposure in C57BL/6 N mice carrying the human AS3MT gene: the role of sex and exposure window.Archives of toxicology · 2026Article
- Potential Drug-Drug Interactions in Patients Undergoing Hemodialysis:Saudi medical journal · 2026Observational
- Defining the Roles of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Management of Chronic Kidney Disease in Adults with Type 2 Diabetes With or Without Overweight/Obesity: An International Delphi Consensus.Advances in therapy · 2026Article
- Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Population-Based Study.Diabetes, obesity & metabolism · 2026Article
- Connexins in metabolic control: linking brain cellular communication to systemic homeostasis.Life medicine · 2026Review
- sncRNA levels predict SNORD105B is a novel biomarker of chronic kidney disease risk and SGLT2 inhibitor response in type 2 diabetes.Molecular therapy. Nucleic acids · 2026Article
- Plasma Erythropoietin Levels and Anemia in Vietnamese Patients With Type 2 Diabetes and Chronic Kidney Disease: 2018-2019.Health science reports · 2026Article
- Phenotype-Specific Heterogeneity in Acute Kidney Injury, Dialysis, and Mortality Among Hospitalized Patients with Chronic Kidney Disease: A National Retrospective Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Succinylation modification in diabetes and diabetic complications: Mechanisms and functions (Review).Molecular medicine reports · 2026Review
- Alarm Fatigue and Turnover Intention Among Haemodialysis Nurses: The Mediating Role of Professional Quality of Life.Nursing open · 2026Article
- Global, regional, and national burden of diabetes mellitus type 2-related chronic kidney disease from 1990 to 2021 and projections to 2040.Journal of family medicine and primary care · 2026Article
- Immunogenicity and reactogenicity of the adjuvanted respiratory syncytial virus vaccine in patients with chronic kidney disease.Clinical kidney journal · 2026Article
- Uncovering core diseases in temporal trajectories of cardiovascular-kidney-metabolic (CKM) syndrome in UK Biobank: network-based study.Scientific reports · 2026Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes is a complicated, chronic condition that requires ongoing medical attention as well as multiple risk-reduction measures beyond glucose control. The prevalence of chronic kidney disease (CKD) is highly variable in different parts of the world due to various environmental, ethnic, socioeconomic, and rural-urban differences. Diabetes is the leading cause of CKD. This study aimed to estimate the global prevalence of CKD and its associated factors among type 2 diabetes(T2DM) patients, provide scientific evidence for a better understanding of the burden of CKD among diabetes mellitus type 2 patients, and design interventional strategies.
methodsPreferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) checklist guideline was followed for this review and meta-analysis. The electronic databases (Pub Med, Cochrane Library, Google Scholar, and grey literature) were searched to retrieve articles by using keywords. Joanna Briggs Institute Meta-Analysis of Statistics Assessment and Review Instrument was used to assess the quality of studies. The meta-analysis was conducted using STATA 17 software. The Meta logistic regression was computed to present the pooled prevalence and Odds ratio (OR) of the determinate factors with a 95% confidence interval (CI).
resultsIn this systematic review and meta-analysis 20 studies were done in 13 different countries. The pooled magnitude of chronic kidney disease among type 2 DM patients was 27% (95% CI 21%, 33%). The prevalence of chronic kidney disease differs across countries, with the maximum in the USA and the lowest in the United Arab Emirates. Patients with CKD have an elevated risk of severe renal and cardiovascular morbidity and mortality. Renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists, and, more recently, non-steroidal mineralocorticoid receptor antagonists are among the medications that have been demonstrated to slow the progression of CKD. In this systematic review and meta-analysis increased age, obesity, having a history of type 2 diabetes mellitus, smoking history, presence of hypertension, and cardiac heart disease were factors significantly associated with the presence of chronic kidney disease among type 2 diabetic patients.
conclusionsThe prevalence of chronic kidney disease among type 2 diabetes mellitus patients was high based on the included 20 articles. The review reported that old age, hypertension, cardiac disease, smoking, obesity, and duration of diabetes mellitus was predictor variable for chronic kidney disease among type 2 diabetic patients. Therefore, in order to lower the morbidity and mortality from chronic kidney disease among type 2 diabetic patients, it is advised to develop both preventive and curative intervention strategies, such as raising awareness, creating a supportive environment, and prescribing appropriate medication at an early stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.